This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignees: Genentech, Inc., National Cancer Center, Ventana Medical Systems, Inc.. Active years: 2026.
Company Filing History:
1 out of 3,292 
1 out of 263 
1 out of 548 
Years Active: 2026
Title: Akio Kaito: Innovator in Cancer Biomarkers
Introduction
Akio Kaito is a notable inventor based in Kashiwa, Japan. He has made significant contributions to the field of cancer research, particularly in the area of biomarkers. His innovative work focuses on improving the predictability of responses to HER2-directed therapies in cancer treatment.
Latest Patents
Kaito holds a patent titled "HER2 heterogeneity as a biomarker in cancer." This patent describes a method for predicting responsiveness to HER2-directed therapy by assessing HER2 heterogeneity in tumors. The method involves contacting a tumor sample with a biomarker-specific reagent that binds to HER2 protein, detecting HER2 protein in the sample, and using nucleic acid probes to assess HER2 genomic DNA and RNA status. The scoring of HER2 protein, gene, and RNA allows for the prediction of tumor responsiveness to therapy based on specific scoring criteria.
Career Highlights
Throughout his career, Akio Kaito has worked with prominent companies in the biotechnology sector. He has been associated with Ventana Medical Systems, Inc. and Genentech, Inc., where he contributed to advancements in cancer diagnostics and treatment.
Collaborations
Kaito has collaborated with esteemed colleagues in his field, including Atsushi Ochiai and Hiro Nitta. These partnerships have furthered his research and development efforts in cancer biomarker technologies.
Conclusion
Akio Kaito's innovative work in cancer biomarkers exemplifies the impact of research on improving treatment outcomes for patients. His contributions continue to influence the field of oncology and enhance the understanding of tumor heterogeneity.